Shah Preetam 4
4 · Elicio Therapeutics, Inc. · Filed Feb 3, 2026
Research Summary
AI-generated summary of this filing
Elicio (ELTX) CFO Shah Preetam Receives RSUs and Stock Options
What Happened Shah Preetam, Chief Strategy and Financial Officer of Elicio Therapeutics (ELTX), received equity awards on February 2, 2026: 24,000 restricted stock units (RSUs) and 47,900 stock options (reported as a derivative grant). The Form 4 reports an acquisition price of $0.00 for both entries (total reported value $0 on the form). These are grants/awards (compensation), not open-market purchases or sales.
Key Details
- Transaction date: 2026-02-02; Form 4 filed 2026-02-03 (timely filing).
- Awards: 24,000 RSUs (reported as A) and 47,900 options/derivative awards (reported as A, derivative).
- Reported price: $0.00 for both entries (Form 4 shows $0 acquisition amount).
- Shares owned after transaction: not stated in the provided excerpt of the filing.
- Footnotes:
- F1 (RSUs): 25% vest on Feb 2, 2027 (one year after grant), remainder vest in annual installments over the next three years, subject to continued service; each RSU converts to one share upon vesting.
- F2 (Options): 25% of the options vest on Feb 2, 2027; remaining options vest monthly over the following three years, subject to continued service.
- Role: Reporting person listed as Chief Strategy and Financial Officer (insider executive).
Context RSUs become actual shares only when they vest; stock options must vest and then be exercised to convert into shares (and may have an exercise price and tax implications). These awards are company compensation grants and do not, by themselves, signal buying or selling in the open market. The derivative entry simply indicates option awards subject to future vesting/exercise.
Insider Transaction Report
- Award
Common Stock
[F1]2026-02-02+24,000→ 24,000 total - Award
Stock Option (Right to Buy)
[F2]2026-02-02+47,900→ 47,900 totalExercise: $8.10Exp: 2036-02-02→ Common Stock (47,900 underlying)
Footnotes (2)
- [F1]Represents restricted stock units ("RSUs") that will vest as to 25% of the RSUs on February 2, 2027, the first anniversary of the grant date, with the remaining RSUs vesting in annual installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates. Each RSU represents the right to receive one share of common stock, par value $0.01 per share, of the Issuer.
- [F2]The stock option vests and becomes exercisable as to 25% of the options on February 2, 2027, the first anniversary of the grant date, with the remaining options vesting in monthly installments over a three-year period thereafter, subject to the Reporting Person's continued service to the Issuer through the applicable vesting dates.